In spite of vasopressor agents, anti-arrhythmic drugs, early ambulation, and anticoagulant therapy the mortality among patients with acute myocardial infarction is almost 40%/,O .
Intensive-care units may reduce this figure, but other attempts to lower the mortality should be sought. Langsjoen et al. (1963) reported the beneficial effect of low-molecular-weight dextran (mean molecular weight 40,000) in acute infarction, the mortality being reduced from 46.6 to 17.6%. Two years later Langsjoen (1965) confirmed his favourable impression of this treatment. Linden (1964) reported a reduction of the mortality from 33 to 15% in a small series of patients with myocardial infarction receiving low-molecular-weight dextran. Both these stud-es were, however, carried out without proper controls and therefore do not admit of definite conclusions.
Theoretically, low-molecuiar-weight dextran has many advantages. It has antithrombotic properties (Bryant et al., 1963) ; it increases plasma volume (Gelin et al., 1961) and may thus prevent shock; it improves blood-flow (Gelin and Thoren, 1961) by reducing viscosity and may therefore improve circulation at the border of the infarction, thereby limiting its extension. It has an antisludging effect (Long et al., 1962) , which will improve microcirculation. Sludging of the red cells is a frequent finding in myocardial infarction (Bloch, 1955) , and it can itself produce myocardial infarction (Long et al., 1962) .
Theoretically, 500 ml. of 10% low-molecular-weight dextran binds 1,000 ml. of water. The increase in plasma volume will depend on the injected amount, on the infusion-time, and on the renal function. Dextran molecules of less than 50,000-60,000 are cleared by the kidney (Arturson and Wallenius, 1963 Myocardial infarction was defined according to the standard rules of this department (Enger et al., 1963) , requiring typical E.C.G. pattern with Q waves or ST changes. When the E.C.G. pattern was not obvious the diagnosis wAs made if three of the following criteria were present: a rise in the sedimentation rate, serum glutamic oxaloacetic transaminase (G.O.T.) valies above 40 units, a typical temperature curve, and a lucocyte count above 9,000.
The patients admitted to the study were randomized into two groups according to a preconceived list. Separate criteria were made for the two sexes and for the patients with recognized previous infarction.
Treatment
According to Langsjoen (1963) 1,500 ml. of a 10% solution of low-molecular-weight dextran should be given daily for three days in a continuous drip. We carried out a pilot study with this procedure. Of the 13 patients so treated eight died. In some of these frank pulmonary congestion developed though there had been no previous signs of left ventricular failure. The patients felt uncomfortable with the three-day continuous drip. Rheomacrcdex did not influence the clotting or the fibrinolytic mechanism, but the bleeding-time (modified Ivy method) was almost doubled (from 5 to 9.2 minutes) at the end of the three days. As the patients also received anticoagulant therapy, we felt that the effect on the bleeding-time introduced a tendency to bleed of possible clinical importance, since shockthreatened patients can hardly afford even a minor loss. When, therefore, Linden (1964) reported encouraging results similar to those of Langsjoen with a less intensive regime we decided to follow his procedure. Rheomacrodex 500 ml. was given intravenously over five hours as soon as possible after admission. This was repeated twice during the first 48 hours. This method did not influence the bleeding-time. If frank clinical signs of pulmonary-congestion developed the low-molecular-weight dextran infusion was discontinued.
Both groups received routine treatment-including vasopressor agents, salt-restriction, digitalis, antiarrhythmic drugswhen required. Anticoagulant therapy, without initial heparin, was given to all patients. In addition one group received Rheomacrodex as described. The study was not double-blind We did not want to infuse the control group with glucose or saline as we were not convinced that this would be completely harmless.
Results
Of 130 patients who entered the study, 67 received Rheomacrodex and 63 did not. In 28 the original diagnosis of a myocardial infarction could not be confirmed-18 were in the control group and 10 in the treated group. Of the 102 patients with a proved infarction, 57 were treated and 45 were controls (Table I) . Table II provides information on the comparability of the groups. There were minor differences, but on the whole there is no reason to believe that the groups differed prognostically. About half of the patients in the treated series had the Rheomacrodex infusion started within six hours after the onset of chest pain, and 75% within 12 hours. In nine patients the infusion had to be stopped because of clinical signs of increasing pulmonary congestion. Four of these patients died-two on the second day, one on the ninth day, and one on the 25th day. In three the infusion was not completed because of death on the first day. These patients had each received 500 ml. of Rheomacrodex ; one of them developed severe pulmonary congestion. The treatment with Rheomacrodex was thus completed in 45 of the 57 patients. treated group, but on the second day it was higher and remained so. The difference between the two groups in respect of the mean increase of serum G.O.T. from the first to the second day is statistically significant (P<0.01). Fig. 2 gives the corresponding values for the sedimentation rate during the first 10 days. The small difference on the first day increased slightly during the next day, and the sedimentation rate remained higher in the treated group. Fig. 3 gives the mean thrombotest curves during the stay in hospital. The intensity of the anticoagulant therapy was satisfactory, and the same in the two groups. Table III shows pertinent data on the patients during their stay in hospital. Congestive heart failure developed significantly more often in the treated patients than in the controls (0.01<P< 0.05). Pneumonia, post-infarction syndrome, and arrhythmia were also more frequent in the treated series, though the differences between the groups were not statistically significant. The percentage of patients needing vasopressor agents was the same. There was no thromboembolic complication in either group and only one minor bleeding episode in the control series. The mean duration of the hospital stay was slightly longer in the treated group, mainly because of the patients with post-infarction syndrome. ..3
,.I
..,
Discussion
In the pilot study we followed the procedure of Langsjxoen, giving continuous infusion of low-molecular-weight dextran, 1,500 ml. a day for three days. The patients felt uncomfortable. Since we introduced a tendency to bleed, and as pulmonary congestion developed in some of the patients, we believe that this intensive treatment might be harmful. The simplified procedure of Lindrn (1964) had apparently given the same striking result on mortality and was therefore adopted. A comparison between the two groups with verified infarction showed that they were well matched, though there were more treated patients with hypertension. The course of the disease seemed to differ in the two series, as more treated patients developed congestive heart failure, post-infarction syndrome, arrhythmia, and pneumonia. The latter complication may be a consequence of the pulmonary congestion. The The latter mortality is remarkably low. This is most probably related to our criteria of selection of patients, particularly to the exclusion of those showing obvious clinical sign's of pulmonary congestion. The exclusion of old patients and of those dying on admission will further reduce the mortality in the remaining patients. Any comparison with previous experience has little meaning, as it is almost impossible retrospectively to select a comparative " control " group.
From Table I we can calculate that in the patients with coronary heart disease a diagnosis of acute myocardial infarction was maintained in 88% of the treated series against 75{.J., of the controls. Though this difference is not statistically significant, it may indicate that in patients with impending infarction Rheomacrodex actually enhanced the development of myocardial infarction or at least influenced some of our diagnostic criteria.
Our results should perhaps be compared directly only with those of Linden (1964) Rheomacrodex was supplied by Pharmacia, Uppsala, Sweden.
Life-tables can be of value in assessing the social problem which a disease presents and in evaluating the success of different methods of treatment. Two methods of constructing a lifetable are available if a hospital series is used: (1) entering the patient from the age at proved diagnosis, and (2) entering the patient from birth. The first method will probably overestimate mortality, especially when diagnosis tends to be made shortly before death. The second will probably underestimate mortality, except in surveys of specific geographical areas in which all patients with the disease may be expected to be ascertained. Cystic fibrosis is the commonest autosomal recessively determined disease of childhood. The best estimate of incidence in children of European stock is probably that of Danks, Allan, and Anderson (1965) , which gives an incidence of approximatelv I in 2,400 live births.
Source of Case Material
A survev has been made of 498 children attending the Hospital for Sick Children between 1943 and midsummer 1964 who were coded in the hospital records as suffering or possibly suffering from cystic fibrosis. One further case was identified from a search of the post-mortem index, giving a total of 499 cases. Of these cases 399 were coded as suffering from cystic fibrosis and 100 from cystic fibrosis presenting with meconium ileus. Below are given the clinical and laboratory data resulting from the invesigation.
Cystic Fibrosis Not Presenting as Meconium Ileus
Examination of the case material disclosed pronounced variation in both the presence and the degree of characteristic clinical features. The diagnostic laboratory data consist of tests of tryptic activity of the duodenal juice or the sodium content of the sweat. As would be expected for cases collected over a period of more than 20 years, one or both tests had not always bleen carried out.
The variability both in clinical manifestation and in laboratory data is of potential importance in the construction of a life- (1962) . Inability to digest gelatin at a titre of 1 :100 of the juice in the case of the two former methods, and a tryptic activity of the juice of less than 7 units by the latter method, were regarded as confirmatory. In all instances where the pH of the juice was stated to be below 7, or "acid," the results of the test have been excluded.-Prior to 1959 estimation of the sodium content of the sweat was determined by the method of Shwachman, Higgins, and Dooley, as quoted by Shwachman and Leubner (1955) , and subsequently by the method of Gibson and Cooke (1959) . By either method a sodium level of 70 mEq/"K or I, or greater, was considered confirmatory.
The results of the pilocarpine iontophoresis method have been accepted only in those instances where the weight of sweat obtained was at least 100 mg. McKendrick (1962) discussed the effect of age on the sodium content of the sweat and concluded that, in infancy, levels as low as 50 mEq/1. cffer strong evidence of the disease. In the present series there were seven patients in whom the sodium content of the sweat was found to lie between 50 and 70 mEq/l. Of these, four were below the age of 1 year at the time of estimation, and their diagnosis has therefore been accepted as having been confirmed. Laboratory data obtained from tests done at other hospitals were not used in the classification of cases.
The four primary groups were as follows:
